Barbara E. Bierer, M.D.
Chairman of the Board of Trustees, Edward P. Evans Foundation
Professor of Medicine , Harvard Medical School
Division of Global Health Equity, Department of Medicine
Brigham and Women’s Hospital
Barbara E. Bierer, M.D., a hematologist-oncologist, is Professor of Medicine at Harvard Medical School and the Brigham and Women’s Hospital. Dr. Bierer co-founded and now leads, as faculty co-director, the Multi-Regional Clinical Trials (MRCT) Center of BWH and Harvard, a University-wide and collaborative effort to improve standards for the planning and conduct of clinical trials in the developing world. She is the Program Director of the Regulatory Foundations, Law and Ethics Program of the Harvard Catalyst, the Harvard Clinical and Translational Science Award. From 2003-2014, she served as Senior Vice President, Research, at the BWH and initiated the Brigham Research Institute and the Innovation Hub (iHub), a focus for entrepreneurship and innovation. In addition, she established and directed the Center for Faculty Development and Diversity at the BWH.
In addition to her academic responsibilities, Dr. Bierer serves as served as Chair of the Board of Trustees of the Edward P Evans Foundation, a foundation supporting biomedical research. In addition, she serves on the Board of Directors of Public Responsibility in Medicine and Research (PRIM&R), dedicated to promoting the ethical conduct of biomedical and behavioral research; Management Sciences for Health (MSH), an international organization working in partnership globally to strengthen health care, local capability, and access. Previously, she served as the Chair of the Secretary’s Advisory Committee for Human Research Protections, Department of Health and Human Services from 2008-2012. She is currently a member of the National Academies of Sciences Committee on Science, Technology and the Law. She has authored or co-authored over 180 publications and is on the editorial boards of a number of journals including Current Protocols of Immunology.
Dr. Bierer received a B.S. from Yale University and an M.D. from Harvard Medical School.
Robert S. Evans
Trustee, Edward P. Evans Foundation
Robert S. Evans was born in Pittsburgh, Pennsylvania in 1944. He received a B.A. degree in History from the University of Pennsylvania in 1966, and an MBA from Columbia Business School in 1968.
He served as Chairman and CEO of Craneco from 1984 to 2001 when he retired as CEO and remained Chairman. From 1986 to 1995 he held the additional responsibilities of President and COO. Mr. Evans was also Chairman and Chief Executive Officer of Medusa Corporation from 1988 to 1998.
In addition, he serves as a Director of Huttig Building Products, of St. Louis, MO; Chairman of HBD Industries, Inc. of Bellefontaine, Ohio; a member of Columbia Business School Board of Overseers; and he is also a Life Time Trustee of Eaglebrook School. Edward P. Evans was his brother.
William S. Farish, Jr.
Trustee, Edward P. Evans Foundation
William S. Farish, Jr. was born in Houston, TX in 1964. He graduated with a B.A. from the University of Virginia in 1987. From 1987 to 1992 he worked in the financial industry in Houston before serving as the personal aide to President George H. W. Bush. Afterwards, Mr. Farish joined the management of his family’s Lane’s End Farm, where he leads all aspects of one of the largest thoroughbred breeding operations in the United States.
Mr. Farish is a highly active promoter of thoroughbred racing and serves on a number of related foundations. He has been Chairman of the Board of the Breeder’s Cup for over five years (2006-2011; 2013-present). In addition to his numerous equine interests, Mr. Farish devotes much of his time to philanthropy, serving as a Board Member or Trustee for institutions devoted to educational or health care related missions such as the University of Kentucky, Markey Cancer Center Foundation, and the Edward P. Evans Foundation.
After launching Operation Match, the first college computer dating service in 1965, Jeff Tarr went on to pioneer the use of computers on Wall Street by creating algorithms for investing in risk arbitrage.
Mr. Tarr currently chairs Junction Advisors and divides his spare time among his family, his numerous philanthropic interests, and a burgeoning interest in thoroughbred horse racing.
Michael D. Lewis, Ph.D.
President, Edward P. Evans Foundation
Michael Lewis has over thirty years’ experience in the pharmaceutical industry discovering and developing small molecule and biological products before joining the Edward P. Evans Foundation in 2014. For many years he led the pharmaceutical discovery research at a major Pharma subsidiary focusing on new technologies for the treatment of cancer and immunological disorders. Dr. Lewis believes that recent scientific advancements in hematology hold great promise for the discovery and development of transformational MDS therapies that could make a real difference in the lives of patients. He believes that the Edward P. Evans Foundations is ideally positioned to catalyze these advances.
Dr. Lewis received his B.S. degree from the Massachusetts Institute of Technology and his Ph.D. from Harvard University.
Scott Hiebert, Ph.D.
Chairman of the Scientific Advisory Board, Edward P. Evans Foundation
Professor of Biochemistry and Medicine
Associate Director for Basic Research
Vanderbilt-Ingram Cancer Center
School of Medicine, Vanderbilt University
Dr. Hiebert received his Ph.D. from Northwestern University in molecular virology before pursuing postdoctoral studies at Duke University. He initiated his independent research laboratory at St. Jude Children’s Research Hospital studying the E2F family of transcription factors and their regulation by the retinoblastoma tumor suppressor. While at St. Jude, he started a research program in acute leukemia studying the t(8;21), which is one of the most frequent chromosomal translocations in acute myeloid leukemia. He also studied the inv(16) in AML and the t(12;21) in childhood B cell acute leukemia. In 1997 Dr. Hiebert moved to Vanderbilt University School of Medicine and in 2000 he was tapped to lead the Vanderbilt-Ingram Cancer Center’s Program in Signal Transduction and Cell Proliferation. In 2008, Dr. Hiebert was named an Ingram Professor of Cancer Research and became the Associate Director for Basic Research in the cancer center. In 2010 he also assumed the duties of Associate Director for Shared Resources. In 2013 he was named the Hortense B. Ingram Professor of Cancer Research. He has been continuously funded by the ACS and the NIH since 1992, leads a National Cancer Institute funded training program for graduate students and postdoctoral fellows that is in its 28th year, and is the principal investigator for Vanderbilt’s American Cancer Society Institutional Research grant that is in its 52nd year. He has served as a reviewer for the NCI, Leukemia and Lymphoma Society, and the American Cancer Society, and served on the American Cancer Society’s Council for Extramural Grants. His research interests include hematopoietic stem cell functions, epigenetics, and the mechanism of action of epigenetic drugs, and he has authored over 140 manuscripts.